Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for recent-onset type 1 diabetes
ACTRN12620000239965Phase 2Completed
- Sponsor
- St Vincent's Institute of Medical Research
- Start
- Dec 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of baricitinib in diabetes mellitus type 1 (T1D), sponsored by St Vincent's Institute of Medical Research. Primary endpoint: Change from baseline in plasma C-peptide AUC over 2 hours following a mixed meal. Started Dec 2020; status: completed.
02
Drugs
baricitinib
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ACTRN12620000239965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000239965.